effectiveness of a state-of-the-art software application for smart phones (i.e., mobile application), “Solar Cell.” This software application supports decision-making related to sun protection and exposure by Americans to reduce the risk of developing skin cancer attributable to chronic and severe UV exposure and developing other cancers attributable to vitamin D deficiency. The Solar Cell mobile smart phone application combines personal and behavior data with geo-spatial data (i.e., UV Index forecast, time, and location) and delivers actionable sun protection advice to reduce risk of skin cancer. Frequency of Response: Once. Affected Public: Individuals. Type of Respondents: Adults (18 and over) from the U.S. population who own Android smart phones. The annual reporting burden is estimated at 673 (see Table below). There are no Capital Costs, Operating Costs, and/or Maintenance Costs to report.

A.12–1—ESTIMATES OF ANNUAL BURDEN HOURS

<table>
<thead>
<tr>
<th>Type of respondents</th>
<th>Instrument</th>
<th>Number of respondents</th>
<th>Frequency of response</th>
<th>Average time per response (minutes/hour)</th>
<th>Annual burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults</td>
<td>Screener (Appendix G)</td>
<td>1,875</td>
<td>1</td>
<td>15/60 (0.25)</td>
<td>469</td>
</tr>
<tr>
<td></td>
<td>Pre-test (Appendix A)</td>
<td>245</td>
<td>1</td>
<td>20/60 (0.33)</td>
<td>82</td>
</tr>
<tr>
<td></td>
<td>Post-test (Appendix B)</td>
<td>184</td>
<td>1</td>
<td>40/60 (0.66)</td>
<td>123</td>
</tr>
<tr>
<td>Totals</td>
<td></td>
<td>2,304</td>
<td></td>
<td></td>
<td>673</td>
</tr>
</tbody>
</table>

Request for Comments: Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Patricia Weber, DrPH, Program Director, NCI/NIH, SBIR Development Center, 6116 Executive Blvd., Suite 402, Rockville, MD 20852 or call non-toll-free number (301) 594–8106 or email your request, including your address to: weberpa@mail.nih.gov.

Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

DATED: January 11, 2012.

Vivian Horovitch-Kelley,
NCI Project Clearance Liaison, National Institutes of Health.

[FR Doc. 2012–872 Filed 1–18–12; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Human Genome Research Institute; Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of meetings of the National Advisory Council for Human Genome Research.

The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council for Human Genome Research.

Date: February 13, 2012, 3 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications and/or proposals.

Place: National Institutes of Health, 5635 Fishers Lane Terrace Level Conference Room, Rockville, MD 20892.

Closed: February 14, 2012, 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications and/or proposals National Institutes of Health, 5635 Fishers Lane, Terrace Level Conference Room, Rockville, MD 20892.

Contact Person: Mark S. Guyer, Ph.D., Director for Extramural Research National Human Genome Research Institute, 5635 Fishers Lane, Suite 4076, MSC 9305, Bethesda, MD 20892, (301) 496–7531 guyerm@mail.nih.gov.

Name of Committee: National Advisory Council for Human Genome Research.

Date: May 21–22, 2012.

Open: May 21, 2012, 8:30 a.m. to 3 p.m.

Agenda: To discuss matters of program relevance.

Place: National Institutes of Health, 5635 Fishers Lane, Terrace Level Conference Room, Rockville, MD 20892.

Closed: May 21, 2012, 3 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications and/or proposals.

Place: National Institutes of Health, 5635 Fishers Lane, Terrace Level Conference Room, Rockville, MD 20892.

Closed: May 22, 2012, 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications and/or proposals.

Place: National Institutes of Health, 5635 Fishers Lane, Terrace Level Conference Room, Rockville, MD 20892.

Contact Person: Mark S. Guyer, Ph.D., Director for Extramural Research National Human Genome Research Institute, 5635 Fishers Lane, Suite 4076, MSC 9305, Bethesda, MD 20892, (301) 496–7531 guyerm@mail.nih.gov.

Name of Committee: National Advisory Council for Human Genome Research.

Date: September 10–11, 2012.

Open: September 10, 2012, 8:30 a.m. to 3 p.m.
DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation Cooperative Agreement (U01).

Date: February 7–8, 2012.
Time: 2 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: James T. Snyder, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892 (301) 451–7383, james.snyder@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)


Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2012–884 Filed 1–18–12; 8:45 am]
BILLING CODE 4140–01–P